IN THE NEWS
Cell Care Therapeutics is a Los Angeles based preclinical stage company developing regenerative immunotherapies derived from the secretions of adult stem cells to treat severe inflammatory and degenerative eye diseases that may ultimately lead to vision loss. The technology also holds the potential for use in the treatment of other inflammatory diseases.
FOR RETINAL DISEASE
Cell Care Therapeutics is developing an off the shelf, injectable, stem cell secretome product containing exosomes. It is increasingly recognized that the predominant therapeutic qualities of adult stem cells come from the “secretome”, comprised of proteins, micro RNA, and exosomes secreted by the cells, rather than from the cells themselves.
Mesenchymal stem cell (MSC) transplants have shown efficacy for regeneration in inflammatory diseases leading to recent EMA approval for Crohn’s. MSCs currently show great promise in clinical trials for treating degenerative eye diseases driven by inflammation and oxidative stress. Despite promising efficacy, a product comprised of living stem cells presents commercial challenges; stem cell therapies are expensive, difficult to dose, routinely lose viability during shipping and transplantation, can migrate away from the injection site, and are not available off-the- shelf. Cell Care's technology overcomes these challenges.
Cell Care's biologic halts and reverses progression of oxidative stress, inflammation, and fibrosis in retina thereby preventing vascular leakage and restoring vision in numerous degenerative retinal diseases.